Silo Pharma's QwikAgents Adds NVIDIA API Keys and Hermes Runtime, Expanding AI Agent Flexibility

By Trinzik•
Silo Pharma's QwikAgents platform now supports customer-supplied NVIDIA API keys and the Hermes runtime, giving businesses greater control and choice in AI agent deployment.
Silo Pharma's QwikAgents Adds NVIDIA API Keys and Hermes Runtime, Expanding AI Agent Flexibility

Silo Pharma (NASDAQ: SILO) announced that its wholly owned managed AI agent subsidiary, QwikAgents, has expanded its platform with support for customer-supplied NVIDIA API keys and the addition of the Hermes agent runtime. This development matters because it gives enterprises more flexibility and control over their AI agent infrastructure, potentially accelerating adoption of AI solutions across industries.

Customers can now use their own NVIDIA API keys to access NVIDIA Nemotron models, making NVIDIA the fifth supported bring-your-own-key provider alongside Anthropic, OpenAI, Google, and DeepSeek. This means businesses can leverage existing NVIDIA agreements and manage costs more effectively while tapping into advanced AI models. The bring-your-own-key model is increasingly important as companies seek to avoid vendor lock-in and maintain control over their AI spending.

QwikAgents also added Hermes as an alternative to the OpenClaw runtime, allowing customers to select either option when creating an AI agent. Both runtimes operate on QwikAgents infrastructure, which includes managed hosting, persistent memory, model routing, and dedicated compute. By offering a choice of runtimes, QwikAgents addresses diverse customer preferences and technical requirements, which could lead to higher satisfaction and retention.

The implications extend beyond mere technical upgrades. For Silo Pharma, a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, the move signals a strategic push into the AI agent market. While its therapeutic focus remains on underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, the AI subsidiary could provide a new revenue stream and diversify its business portfolio. The company's pipeline includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis, with research conducted in collaboration with leading universities and laboratories.

For the AI industry, QwikAgents' expansion reflects a broader trend toward modular, customizable AI solutions. As businesses increasingly demand tailored AI agents, platforms that offer multiple model providers and runtimes may gain a competitive edge. The ability to bring your own key and choose your runtime could lower barriers to entry and foster innovation.

Investors and industry observers can find the full press release at https://ibn.fm/AXpqr. The latest news and updates relating to SILO are available in the company's newsroom at https://ibn.fm/SILO. This announcement was distributed through AINewsWire, a specialized communications platform focused on AI advancements, which is part of the Dynamic Brand Portfolio at IBN. IBN provides access to a vast network of wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. For more information, visit www.AINewsWire.com.

Trinzik

Trinzik

@trinzik

Trinzik AI is an Austin, Texas-based agency dedicated to equipping businesses with the intelligence, infrastructure, and expertise needed for the "AI-First Web." The company offers a suite of services designed to drive revenue and operational efficiency, including private and secure LLM hosting, custom AI model fine-tuning, and bespoke automation workflows that eliminate repetitive tasks. Beyond infrastructure, Trinzik specializes in Generative Engine Optimization (GEO) to ensure brands are discoverable and cited by major AI systems like ChatGPT and Gemini, while also deploying intelligent chatbots to engage customers 24/7.